RNS Number : 5700B Renalytix PLC 05 June 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9 LONDON and SALT LAKE CITY , June 5, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter
Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage LONDON and CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) , the first company to develop and commercialize an
RNS Number : 5773A Renalytix PLC 25 May 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes Model expected to accelerate deployment of
RNS Number : 1093A Renalytix PLC 22 May 2023 Renalytix plc ("Renalytix" or the "Company") Expansion of insurance coverage for KidneyIntelX TM LONDON and SALT LAKE CITY , May 22, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) reports the expansion of insurance coverage for KidneyIntelX with
RNS Number : 0238Z Renalytix PLC 11 May 2023 Renalytix plc ("Renalytix" or the "Company") Notice of General Meeting and Posting of Circular LONDON and SALT LAKE CITY , May 11, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that a circular containing a notice convening a General
Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple Physician Specialties KidneyIntelX individualizes clinical decisions beginning at primary care where impacts of new therapies, blood pressure strategies and timely
RNS Number : 6476W Renalytix PLC 19 April 2023 Renalytix plc ("Renalytix" or the "Company") New Published Real-World Evidence Shows KidneyIntelX™ Utility Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple
In a clinical decision effectiveness study, KidneyIntelX classified more Black vs non-Black patients as high risk for progression of chronic kidney disease, resulting in increased prescription of SGLT2-inhibitor drug therapy Additional study results illustrate how KidneyIntelX is aligned with the
RNS Number : 8895V Renalytix PLC 12 April 2023 Renalytix plc ("Renalytix" or the "Company") Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting In a clinical decision effectiveness study, KidneyIntelX
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
